Henry D, Lim L L, Garcia Rodriguez L A, Perez Gutthann S, Carson J L, Griffin M, Savage R, Logan R, Moride Y, Hawkey C, Hill S, Fries J T
Centre for Clinical Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, University of Newcastle, New South Wales, Australia.
BMJ. 1996 Jun 22;312(7046):1563-6. doi: 10.1136/bmj.312.7046.1563.
To compare the relative risks of serious gastrointestinal complications reported with individual non-steroidal anti-inflammatory drugs.
Systematic review of controlled epidemiological studies that found a relation between use of the drugs and admission to hospital for haemorrhage or perforation.
Hospital and community based case-control and cohort studies.
(a) Estimated relative risks of gastrointestinal complications with use of individual drugs, exposure to ibuprofen being used as reference; (b) a ranking that best summarised the sequence of relative risks observed in the studies.
12 studies met the inclusion criteria. 11 provided comparative data on ibuprofen and other drugs. Ibuprofen ranked lowest or equal lowest for risk in 10 of the 11 studies. Pooled relative risks calculated with exposure to ibuprofen used as reference were all significantly greater than 1.0 (interval of point estimates 1.6 to 9.2). Overall, ibuprofen was associated with the lowest relative risk, followed by diclofenac. Azapropazone, tolmetin, ketoprofen, and piroxicam ranked highest for risk and indomethacin, naproxen, sulindac, and aspirin occupied intermediate positions. Higher doses of ibuprofen were associated with relative risks similar to those with naproxen and indomethacin.
The low risk of serious gastrointestinal complications with ibuprofen seems to be attributable mainly to the low doses of the drug used in clinical practice. In higher doses ibuprofen is associated with a similar risk to other non-steroidal anti-inflammatory drugs. Use of low risk drugs in low dosage as first line treatment would substantially reduce the morbidity and mortality due to serious gastrointestinal toxicity from these drugs.
比较各种非甾体抗炎药报告的严重胃肠道并发症的相对风险。
对已发现药物使用与因出血或穿孔入院之间存在关联的对照流行病学研究进行系统评价。
基于医院和社区的病例对照研究及队列研究。
(a)使用各药物时胃肠道并发症的估计相对风险,以布洛芬暴露作为对照;(b)最能概括研究中观察到的相对风险顺序的排名。
12项研究符合纳入标准。11项提供了布洛芬与其他药物的比较数据。在11项研究中的10项里,布洛芬的风险排名最低或并列最低。以布洛芬暴露作为对照计算的合并相对风险均显著大于1.0(点估计区间为1.6至9.2)。总体而言,布洛芬的相对风险最低,其次是双氯芬酸。阿扎丙宗、托美丁、酮洛芬和吡罗昔康的风险排名最高,吲哚美辛、萘普生、舒林酸和阿司匹林处于中间位置。较高剂量的布洛芬与萘普生和吲哚美辛的相对风险相似。
布洛芬严重胃肠道并发症风险低似乎主要归因于临床实践中使用的药物剂量低。高剂量时,布洛芬与其他非甾体抗炎药的风险相似。使用低风险药物的低剂量作为一线治疗将大幅降低这些药物所致严重胃肠道毒性的发病率和死亡率。